Crinetics Pharmaceuticals, Inc. Cash Flow Statement
CRNX / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Crinetics Pharmaceuticals, Inc. used $378M in operating cash flow and negative free cash flow of $384M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$465.3M | -$298.4M | -$214.5M | -$163.9M | -$107.6M | -$27.1M | -$9.2M | -$6.0M | -$9.2M | -$6.0M |
| Depreciation & Amortization | $3.9M | $2.8M | $1.1M | $983.0K | $922.0K | $471.0K | $128.0K | $92.0K | $128.0K | $92.0K |
| Operating Cash Flow | -$377.9M | -$230.2M | -$168.6M | -$115.2M | -$88.6M | -$19.5M | -$9.5M | -$5.5M | -$9.5M | -$5.5M |
| Capital Expenditures | $5.8M | $3.8M | $4.7M | $1.7M | $436.0K | $1.1M | $304.0K | $190.0K | $304.0K | $190.0K |
| Free Cash Flow | -$383.7M | -$234.0M | -$173.3M | -$116.9M | -$89.0M | -$20.5M | -$9.8M | -$5.7M | -$9.8M | -$5.7M |
| FCF Margin | -4985.5% | -22525.3% | - | -2467.0% | -8258.3% | -845.1% | -478.4% | -960.6% | - | -960.6% |